Greene Donald Royster1, Kavitha Krishnamoorthy2, John M Csokmay3, Belinda J Yauger3, Rebecca J Chason3, Alan H DeCherney4, Erin F Wolff4, Micah J Hill3. 1. Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Walter Reed National Military Medical Center, Bethesda, Maryland; Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. Electronic address: DonRoysterMD@gmail.com. 2. Department of Obstetrics and Gynecology, University of Miami Jackson Health System, Miami, Florida. 3. Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Walter Reed National Military Medical Center, Bethesda, Maryland. 4. Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Abstract
OBJECTIVE: To evaluate whether intracytoplasmic sperm injection (ICSI) use and E2 on the final day of assisted reproductive technology (ART) stimulation are associated with adverse obstetric complications related to placentation. DESIGN: Retrospective cohort study. SETTING: Large private ART practice. PATIENT(S): A total of 383 women who underwent ART resulting in a singleton live birth. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Adverse placental outcomes composed of placenta accreta, placental abruption, placenta previa, intrauterine growth restriction, preeclampsia, gestational hypertension, and small for gestational age infants. RESULT(S): Patients with adverse placental outcomes had higher peak serum E2 levels and were three times more likely to have used ICSI. Adverse placental outcomes were associated with increasing E2 (odds ratio 1.36, 95% confidence interval 1.13-1.65) and ICSI (odds ratio 3.86, 95% confidence interval 1.61-9.27). Adverse outcomes increased when E2 was >3,000 pg/mL and continued to increase in a linear fashion until E2 was >5,000 pg/mL. The association of ICSI with adverse outcomes was independent of male factor infertility. Interaction testing suggested the adverse effect of E2 was primarily seen in ICSI cycles, but not in conventional IVF cycles. Estradiol >5,000 pg/mL was associated with adverse placental events in 36% of all ART cycles and 52% of ICSI cycles. CONCLUSION(S): ICSI and elevated E2 on the day of hCG trigger were associated with adverse obstetric outcomes related to placentation. The finding of a potential interaction of E2 and ICSI with adverse placental events is novel and warrants further investigation. Published by Elsevier Inc.
OBJECTIVE: To evaluate whether intracytoplasmic sperm injection (ICSI) use and E2 on the final day of assisted reproductive technology (ART) stimulation are associated with adverse obstetric complications related to placentation. DESIGN: Retrospective cohort study. SETTING: Large private ART practice. PATIENT(S): A total of 383 women who underwent ART resulting in a singleton live birth. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Adverse placental outcomes composed of placenta accreta, placental abruption, placenta previa, intrauterine growth restriction, preeclampsia, gestational hypertension, and small for gestational age infants. RESULT(S): Patients with adverse placental outcomes had higher peak serum E2 levels and were three times more likely to have used ICSI. Adverse placental outcomes were associated with increasing E2 (odds ratio 1.36, 95% confidence interval 1.13-1.65) and ICSI (odds ratio 3.86, 95% confidence interval 1.61-9.27). Adverse outcomes increased when E2 was >3,000 pg/mL and continued to increase in a linear fashion until E2 was >5,000 pg/mL. The association of ICSI with adverse outcomes was independent of male factor infertility. Interaction testing suggested the adverse effect of E2 was primarily seen in ICSI cycles, but not in conventional IVF cycles. Estradiol >5,000 pg/mL was associated with adverse placental events in 36% of all ART cycles and 52% of ICSI cycles. CONCLUSION(S): ICSI and elevated E2 on the day of hCG trigger were associated with adverse obstetric outcomes related to placentation. The finding of a potential interaction of E2 and ICSI with adverse placental events is novel and warrants further investigation. Published by Elsevier Inc.
Authors: S L Tan; P Doyle; S Campbell; V Beral; B Rizk; P Brinsden; B Mason; R G Edwards Journal: Am J Obstet Gynecol Date: 1992-09 Impact factor: 8.661
Authors: Diederik A Hoozemans; Roel Schats; Cornelis B Lambalk; Roy Homburg; Peter G A Hompes Journal: Reprod Biomed Online Date: 2004-12 Impact factor: 3.828
Authors: Micah J Hill; Greene Donald Royster; Mae Wu Healy; Kevin S Richter; Gary Levy; Alan H DeCherney; Eric D Levens; Geeta Suthar; Eric Widra; Michael J Levy Journal: Fertil Steril Date: 2015-04-14 Impact factor: 7.329
Authors: Laura A Schieve; Sonja A Rasmussen; Germaine M Buck; Diana E Schendel; Meredith A Reynolds; Victoria C Wright Journal: Obstet Gynecol Date: 2004-06 Impact factor: 7.661
Authors: N Pereira; R T Elias; P J Christos; A C Petrini; K Hancock; J P Lekovich; Z Rosenwaks Journal: Hum Reprod Date: 2017-07-01 Impact factor: 6.918
Authors: Caitlin R Sacha; Daksha Gopal; Chia-Ling Liu; Howard R Cabral; Judy E Stern; Daniela A Carusi; Catherine Racowsky; Charles L Bormann Journal: Fertil Steril Date: 2022-04-23 Impact factor: 7.490
Authors: Bora Lee; Lindsay L Kroener; Ning Xu; Erica T Wang; Alexandra Banks; John Williams; Mark O Goodarzi; Yii-der I Chen; Jie Tang; Yizhou Wang; Vineela Gangalapudi; Margareta D Pisarska Journal: Biol Reprod Date: 2016-10-12 Impact factor: 4.285